Last reviewed · How we verify
Infliximab (Remicade)
Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.
Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | Infliximab (Remicade) |
|---|---|
| Also known as | Remicade, SCH 215596 |
| Sponsor | University of California, San Diego |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
By blocking TNF-α, infliximab reduces the inflammatory cascade that drives autoimmune and inflammatory diseases. This TNF-α inhibition decreases immune cell activation, reduces production of other inflammatory mediators, and promotes apoptosis of inflammatory cells. The drug is effective in conditions where TNF-α plays a central pathogenic role, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
- Psoriasis
- Behçet's disease
Common side effects
- Infections (including serious infections and tuberculosis)
- Infusion reactions
- Headache
- Nausea
- Abdominal pain
- Lupus-like syndrome
- Demyelinating disease
Key clinical trials
- Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
- MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease (NA)
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infliximab (Remicade) CI brief — competitive landscape report
- Infliximab (Remicade) updates RSS · CI watch RSS
- University of California, San Diego portfolio CI